The nation has finally seen the result of decades of discussion concerning the FDA approving a drug whose active ingredient is derived from marijuana.

According to a press release put out by the Food and Drug Administration on Monday, June 25, an oral solution for the treatment of seizures associated with two rare forms of epilepsy have been approved.

The product is called Epidiolex (cannabidiol) and has been fabricated and approved to help treat Lennox-Gastaut syndrome and Dravet syndrome.

Epidiolex has been listed as the very first, FDA-approved drug whose main ingredient is derived from cannabis (tetrahydrocannabinol) also known as THC.

Some of the most common side effects of the drug have been listed as sleepiness, sedation and lethargy, elevated liver enzymes, diarrhea, rash, and fatigue to name a few.

For more information about the drug, either talk to your doctor or visit here.